Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance

Future Microbiol. 2019 Oct;14:1293-1308. doi: 10.2217/fmb-2019-0135. Epub 2019 Oct 1.

Abstract

Aim: Recently approved for use in complicated intra-abdominal infection, eravacycline is a novel fluorocycline with broad spectrum of activity against resistant Gram-negative pathogens. This manuscript is a pooled analysis of two Phase III trials. Clinical efficacy: Clinical cure rates were 86.8% for eravacycline versus 87.6% for ertapenem, and 90.8% for eravacycline versus 91.2% for meropenem in the Intent to Treat (micro-ITT) populations, and 87.0% for eravacycline versus 88.8% ertapenem, and 92.4 versus 91.6% for meropenem in the Modified Intent to Treat (MITT) populations. Safety: Eravacycline is well tolerated, with lower rates of nausea, vomiting and diarrhea than other tetracyclines. Conclusion: Eravacycline is an effective new option for use in complicated intra-abdominal infections, and in particular, for the treatment of extended-spectrum β-lactamase- and carbapenem-resistant Enterobacteriaceae-expressing organisms.

Trial registration: ClinicalTrials.gov NCT01844856 NCT02784704.

Keywords: CRE; ESBL; Gram-negative; antibiotics; antimicrobial resistance; complicated intra-abdominal infection; eravacycline; tetracycline.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Carbapenems / therapeutic use
  • Data Interpretation, Statistical
  • Drug Resistance, Multiple, Bacterial*
  • Enterobacteriaceae / drug effects*
  • Enterobacteriaceae / enzymology
  • Ertapenem / therapeutic use
  • Female
  • Humans
  • Intraabdominal Infections / complications
  • Intraabdominal Infections / drug therapy*
  • Intraabdominal Infections / microbiology*
  • Male
  • Meropenem / therapeutic use
  • Microbial Sensitivity Tests
  • Middle Aged
  • Prospective Studies
  • Tetracyclines / therapeutic use*
  • Young Adult
  • beta-Lactamases

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Tetracyclines
  • eravacycline
  • beta-Lactamases
  • Meropenem
  • Ertapenem

Associated data

  • ClinicalTrials.gov/NCT01844856
  • ClinicalTrials.gov/NCT02784704